In summary, we concluded that BRD4 can serve as a target in pulmonary fibrosis and has the potential to serve as a therapeutic target in lung diseases such as airway remodeling, interstitial lung disease, PAH and COPD [198]. This evidence concerns the gene BRD4 and pulmonary fibrosis.